Start-Ups Move Stem Cell Products Forward On Long Path To Market
Executive Summary
The dream of turning stem cell research into mainstream clinical therapies is making significant progress, as a large number of cell-based clinical studies are currently underway - some 2,700 stem cell clinical trials registered with www.clinicaltrials.gov between February 2000 and June 2010. While several companies have launched stem cell products onto the market, it’s the number of products in the pipeline that is starting to capture the attention of observers – including investors – who believe activity in current clinical trials is a telling sign of where the industry is headed.
You may also be interested in...
Cell-Based Solutions for Neurologic Disease
Emerging tissue-engineering and cell transplantation therapies have the potential to provide solutions to many of the treatment challenges facing neurologists today.
The Future of the Stem Cell Market
The stem cell market is beginning to show signs of significant revenue growth ahead, a development fueled by research in a variety of disease categories, some of which has already produced accepted therapies. In February, about three dozen firms gathered at the 5th Annual Stem Cell Summit, where participants showcased their technology in the hopes of securing financing.
Bioactive Technologies for Bone Replacement
The global market for orthobiologics, comprised primarily of bone replacement materials, reached almost $2 billion in 2009 and is growing at an overall rate of 7%. Medtronic leads in bone replacement with a 45% market share, but overall growth in orthobiologics may come from emerging segments, particular synthetic and stem-cell based technologies.